Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Revive Therapeutics Ltd. > $RVV AGM Sep 19th - Audi Recording !
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(97)
•••
Comment by G1945Von Sep 21, 2022 11:08am
127 Views
Post# 34976390

RE:$RVV AGM Sep 19th - Audi Recording !

RE:$RVV AGM Sep 19th - Audi Recording !


Thank you for posting it.

A question that was asked by Wayne Murphy regarding the 713 patients already dosed. The  
FDA has access to the data that of 213 trial participants. That leaves 500 that they do not have data for to date. However Revive has that data as I understand it from the response given to Wayne. That being said, Revive having that data of the 500 can they not determine from the additional data the success or failure of the trial overall?

Can anyone shed some light on this please?

G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities